Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
via FOX BUSINESS NEWS Markets
https://ift.tt/382GaOd
0 comments:
Post a Comment